Literature DB >> 16617326

HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations.

V De Re1, D Sansonno, M P Simula, L Caggiari, D Gasparotto, M Fabris, F A Tucci, V Racanelli, R Talamini, M Campagnolo, S Geremia, F Dammacco, S De Vita.   

Abstract

We demonstrate that in three cases of MC (two with immunocytoma), the IgM-RF+ component of their cryoprecipitated represents the circulating counterpart of the B-cell receptor (BCR) of the monoclonal overexpanded B-cell population. These IgMs were isolated and used to demonstrate a crossreactivity against both hepatitis C virus (HCV) NS3 antigen and the Fc portion of IgG. Epitopes were identified in a fraction of exemplary samples by using epitope excision approach (NS(31250-1334) and IgG Fc(345-355)). The same phenomenon of crossreactivity has been shown to occur in vivo after immunization of a mouse with the NS3(1251-1270) peptide. To verify if the same reaction was also present in MC samples characterized by an oligo/polyclonal B-cell proliferation, IgM crossreactivity was tested in 14 additional samples. Five out of the 14 were reactive against HCV NS3 and 11 out of 14 were reactive against IgG-Fc peptide. The data support the role of HCV NS3 antigen in a subset of patients with MC, whereas the high frequency of the IgG-Fc epitope suggests that these B cells originate from precursors strongly selected for auto-IgG specificity. We suggest that engagement of specific BCRs by NS3 (or NS3-immunocomplex) antigen could explain the prevalence of IgM cryoglobulins in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617326     DOI: 10.1038/sj.leu.2404201

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage.

Authors:  Maria Paola Simula; Renato Cannizzaro; Vincenzo Canzonieri; Alessandro Pavan; Stefania Maiero; Giuseppe Toffoli; Valli De Re
Journal:  Mol Med       Date:  2010-03-03       Impact factor: 6.354

2.  Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinica Manifestations, and New Therapies.

Authors:  Neal J Schamberg; Gerond V Lake-Bakaar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-09

Review 3.  Hepatitis C virus-induced cryoglobulinemia.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  Kidney Int       Date:  2009-07-15       Impact factor: 10.612

Review 4.  The hepatitis C virus infection as a systemic disease.

Authors:  Anna Linda Zignego; Laura Gragnani; Carlo Giannini; Giacomo Laffi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

Review 5.  The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.

Authors:  Franco Dammacco; Vito Racanelli; Sabino Russi; Domenico Sansonno
Journal:  Clin Exp Med       Date:  2016-03-02       Impact factor: 3.984

6.  Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile.

Authors:  Martha Minopetrou; Emilia Hadziyannis; Melanie Deutsch; Maria Tampaki; Asimina Georgiadou; Eleni Dimopoulou; Dimitrios Vassilopoulos; John Koskinas
Journal:  Clin Vaccine Immunol       Date:  2013-03-06

Review 7.  Relationships between lymphomas linked to hepatitis C virus infection and their microenvironment.

Authors:  Antonino Carbone; Annunziata Gloghini
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 8.  Hepatitis C virus infection and mixed cryoglobulinemia.

Authors:  Gianfranco Lauletta; Sabino Russi; Vincenza Conteduca; Loredana Sansonno
Journal:  Clin Dev Immunol       Date:  2012-07-10

Review 9.  HCV and lymphoproliferation.

Authors:  Anna Linda Zignego; Carlo Giannini; Laura Gragnani
Journal:  Clin Dev Immunol       Date:  2012-07-19

Review 10.  Molecular signature in HCV-positive lymphomas.

Authors:  Valli De Re; Laura Caggiari; Marica Garziera; Mariangela De Zorzi; Ombretta Repetto
Journal:  Clin Dev Immunol       Date:  2012-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.